{"protocolSection": {"identificationModule": {"nctId": "NCT00457626", "orgStudyIdInfo": {"id": "CVAL489K2303E1"}, "secondaryIdInfos": [{"id": "2006-005473-21", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension", "officialTitle": "An Open Label Extension Study to Evaluate Safety, Tolerability, and Efficacy of 18 Weeks of Valsartan Treatment in Children 6 Months-5 Years Old With Hypertension"}, "statusModule": {"statusVerifiedDate": "2021-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-05-25", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-05-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-04-05", "studyFirstSubmitQcDate": "2007-04-05", "studyFirstPostDateStruct": {"date": "2007-04-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-04-28", "resultsFirstSubmitQcDate": "2021-04-28", "resultsFirstPostDateStruct": {"date": "2021-05-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-09-01", "lastUpdatePostDateStruct": {"date": "2021-09-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy, safety and tolerability of long-term use (up to 18 weeks) of valsartan in children 6 months to 5 years old with hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Children", "pediatrics", "High Blood Pressure", "Hypertension", "Valsartan"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 66, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan Open Label", "type": "EXPERIMENTAL", "description": "Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.", "interventionNames": ["Drug: Valsartan"]}], "interventions": [{"type": "DRUG", "name": "Valsartan", "description": "Extemporaneous suspension of valsartan, orally.", "armGroupLabels": ["Valsartan Open Label"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sitting systolic blood pressure (SSBP) measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.", "timeFrame": "Baseline to Week 26"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three SDBP measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.", "timeFrame": "Baseline to Week 26"}, {"measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "An AE was defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.", "timeFrame": "Week 8 to Week 26 of Extension Phase"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n* Participants who qualified and entered the core study.\n* Participants who participated in the core study, completed Period 1 and were re-randomized in Period 2 and continued for at least 3 days in Period 2.\n\nExclusion criteria\n\n* Participants who did not complete Period 1 of the core study.\n* Participants who were re-randomized in Period 2 of core study but did not continue for =\\> 3 days in Period 2 of the core study.\n* Participants who experienced any adverse events considered serious or drug related in the core study.\n* Participants excluded from the core study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Months", "maximumAge": "5 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Hackensack", "state": "New Jersey", "zip": "07601", "country": "United States", "geoPoint": {"lat": 40.88593, "lon": -74.04347}}, {"facility": "Novartis Investigative Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Novartis Investigative Site", "city": "Norfolk", "state": "Virginia", "zip": "23510", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Novartis Investigative Site", "city": "Antwerpen", "zip": "2020", "country": "Belgium", "geoPoint": {"lat": 51.21989, "lon": 4.40346}}, {"facility": "Novartis Investigative Site", "city": "Edegem", "zip": "2650", "country": "Belgium", "geoPoint": {"lat": 51.15662, "lon": 4.44504}}, {"facility": "Novartis Investigative Site", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Novartis Investigative Site", "city": "Laeken", "zip": "1020", "country": "Belgium", "geoPoint": {"lat": 50.87585, "lon": 4.34844}}, {"facility": "Novartis Investigative Site", "city": "Liege", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Novartis Investigative Site", "city": "Goiania", "state": "GO", "zip": "74605-050", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}, {"facility": "Novartis Investigative Site", "city": "Recife", "state": "PE", "zip": "50070-050", "country": "Brazil", "geoPoint": {"lat": -8.05389, "lon": -34.88111}}, {"facility": "Novartis Investigative Site", "city": "Curitiba", "state": "PR", "zip": "80250-030", "country": "Brazil", "geoPoint": {"lat": -25.42778, "lon": -49.27306}}, {"facility": "Novartis Investigative Site", "city": "Marseille", "zip": "13385", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Novartis Investigative Site", "city": "Paris Cedex 19", "zip": "75935", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novartis Investigative Site", "city": "Toulouse", "zip": "31026", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "zip": "H-1083", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Szeged", "zip": "H-6720", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Andh Prad", "zip": "500033", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Mangalore", "state": "Karnataka", "zip": "575001", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "Novartis Investigative Site", "city": "Indore", "state": "M.p.", "zip": "425001", "country": "India", "geoPoint": {"lat": 22.71792, "lon": 75.8333}}, {"facility": "Novartis Investigative Site", "city": "Mumbai", "state": "Maharashtra", "zip": "400026", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Novartis Investigative Site", "city": "Chennai", "state": "Tamil Nadu", "zip": "600008", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Novartis Investigative Site", "city": "New Delhi", "zip": "110 029", "country": "India", "geoPoint": {"lat": 28.63576, "lon": 77.22445}}, {"facility": "Novartis Investigative Site", "city": "Torino", "state": "TO", "zip": "10126", "country": "Italy", "geoPoint": {"lat": 45.07049, "lon": 7.68682}}, {"facility": "Novartis Investigative Site", "city": "Palermo", "zip": "90134", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Novartis Investigative Site", "city": "Gdansk", "zip": "80-952", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Novartis Investigative Site", "city": "Krakow", "zip": "30-663", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Novartis Investigative Site", "city": "Lodz", "zip": "93-338", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Novartis Investigative Site", "city": "Poznan", "zip": "60-572", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Novartis Investigative Site", "city": "Szczecin", "zip": "70-410", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Novartis Investigative Site", "city": "Warszawa", "zip": "04-730", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Novartis Investigative Site", "city": "Gezina", "state": "Gauteng", "zip": "0084", "country": "South Africa", "geoPoint": {"lat": -25.71867, "lon": 28.20673}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7505", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Potchefstroom", "country": "South Africa", "geoPoint": {"lat": -26.71667, "lon": 27.1}}, {"facility": "Novartis Investigative Site", "city": "Pretoria", "zip": "0002", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Novartis Investigative Site", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Novartis Investigative Site", "city": "Izmir", "zip": "35040", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}]}, "referencesModule": {"references": [{"pmid": "23511339", "type": "RESULT", "citation": "Schaefer F, Coppo R, Bagga A, Senguttuvan P, Schlosshauer R, Zhang Y, Kadwa M. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens. 2013 May;31(5):993-1000. doi: 10.1097/HJH.0b013e32835f5721."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study enrolled a total of 66 participants who completed the core study (NCT00435162).", "recruitmentDetails": "The study was conducted at 35 investigative sites in 10 countries from 9 April 2007 to 25 March 2009.", "groups": [{"id": "FG000", "title": "Valsartan Open Label", "description": "Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "60"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Administrative Problems", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Participant's Condition No Longer Requires Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Enrolled extension participants (ENRE) included all participants who were enrolled into this extension study.", "groups": [{"id": "BG000", "title": "Valsartan Open Label", "description": "Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "66"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.4", "spread": "1.41"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "23"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "43"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sitting systolic blood pressure (SSBP) measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.", "populationDescription": "The extension set (ESET) included all participants who entered the extension study, with administration of at least one dose of open-label study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeters of mercury (mmHg)", "timeFrame": "Baseline to Week 26", "groups": [{"id": "OG000", "title": "Valsartan Open Label", "description": "Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg escalated to 2 mg/kg or 4 mg/kg based on MSSBP control after 2 weeks up to 18 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "114.7", "spread": "9.04"}]}]}, {"title": "Change from Baseline at Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.2", "spread": "12.56"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)", "description": "Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three SDBP measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.", "populationDescription": "The ESET included all participants who entered the extension study, with administration of at least one dose of open-label study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 26", "groups": [{"id": "OG000", "title": "Valsartan Open Label", "description": "Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg escalated to 2 mg/kg or 4 mg/kg based on MSSBP control after 2 weeks up to 18 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "70.7", "spread": "11.14"}]}]}, {"title": "Change from Baseline at Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.6", "spread": "11.84"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "An AE was defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.", "populationDescription": "The ESET included all participants who entered the extension study, with administration of at least one dose of open-label study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 8 to Week 26 of Extension Phase", "groups": [{"id": "OG000", "title": "Valsartan Open Label", "description": "Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg escalated to 2 mg/kg or 4 mg/kg based on MSSBP control after 2 weeks up to 18 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}]}], "classes": [{"title": "AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Week 8 to Week 26 of Extension Phase", "description": "The ESET included all participants who entered the extension study, with administration of at least one dose of open-label study drug.", "eventGroups": [{"id": "EG000", "title": "Valsartan Open Label", "description": "Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg escalated to 2 mg/kg or 4 mg/kg based on MSSBP control after 2 weeks up to 18 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 66, "seriousNumAffected": 4, "seriousNumAtRisk": 66, "otherNumAffected": 38, "otherNumAtRisk": 66}], "seriousEvents": [{"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 66}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 66}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 66}]}, {"term": "Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 66}]}, {"term": "Nephrotic syndrome", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 66}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 66}]}, {"term": "Stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 66}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 66}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 66}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 66}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 66}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 66}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 66}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 66}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 66}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 66}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 66}]}, {"term": "Varicella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 66}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 66}]}, {"term": "Anorexia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 66}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 66}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 66}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 66}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "Novartis.email@novartis.com", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Germany", "Sweden", "Switzerland"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}